Trial Profile
A study investigating B cell migration patterns between the peripheral blood and cental nervous system in Multiple Sclerosis patients treated with Natalizumab or fingolimod.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 16 Nov 2016 New trial record
- 17 Sep 2016 Results presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis